Jenburkt Pharmaceuticals is a branded formulations house that began in 1985 with three people making medicines on a loan licence, and has since built a portfolio anchored by pain management and vitamin brands that reach over 400,000 pharmacies. The company went public in 1995 and now operates from its own WHO-GMP compliant plant in Sihor, Gujarat, with an in-house R&D centre recognised by the government’s Department of Scientific and Industrial Research. Its recurring approach is to develop first-in-the-world fixed-dose combinations or to be a fast second-mover at a sharply lower price - a pattern visible from its earliest muscle-relaxant launch in 1991 to its COVID-19 antiviral in 2020. # Business segments Three engines built on the same manufacturing and R&D backbone - a domestic prescription-drug business that carries the house, a small export arm selling the same brands into Africa and Asia, and a young consumer-wellness division that takes the company direct to shoppers for the first time. ## 1. Domestic branded formulations: the prescription engine that built the house **A field force of medical representatives promotes a stable of doctor-prescribed brands - led by a top-10 vitamin brand and a 30-year-old pain franchise - through a network of super stockists whose inventory the company tracks in real time.** - **Nervijen is the flagship** - it ranks No. 6 in India’s Vitamin, Mineral and Nutrients category as of early 2025, making it the single most important brand in the portfolio. - **A pain franchise three decades deep** - Powergesic was launched in 1991 as the first muscle-relaxant-plus-analgesic combination available in India, and today it is prescribed by over 18,000 doctors and accounts for 15% of the company’s portfolio, with line extensions into a gel, a patch and a spray. - **ZIXA is the second pillar** - this anti-inflammatory brand contributes 10% of the portfolio and is used by orthopaedics, GPs, ENT specialists and dentists, giving the company a foothold across multiple prescriber specialties. - **The go-to-market model runs on visibility** - super stockists are integrated into the company’s SAP ERP system, so Jenburkt can see their sales, stock, collections, breakage and expiry, while its medical representatives log over 200,000 doctor interactions a year using tablet-based e-detailing. - **Pricing is partly capped** - products under the Drug Price Control Order can only have their maximum retail price raised by up to 10% in any 12-month period, and the company is exposed to API costs that swing with the rupee’s exchange rate against the dollar and euro. ## 2. International business: the same brands, sold further afield **Exports of branded formulations to distributors in Asia and Africa - a small, legacy business that faces persistent headwinds from currency shortages and regulatory delays in its target markets.** - **Built market by market since 2001** - the first shipment went to Sri Lanka, and the footprint now spans Kenya, Zambia and West Africa, with products like Cartisafe becoming a top-10 brand in Sri Lanka. - **Registrations are the gatekeeper** - the company must obtain product registrations in each country, a slow process that has recently yielded approvals in Congo-Brazza for Ornel Tablet, Ornel Suspension and Powergesic Plus Gel. - **Foreign-exchange shortages choke demand** - customers in Benin, Kenya and Nigeria have struggled to access dollars, while Sri Lanka has been hit by import restrictions, currency depreciation and lower consumer spending, all of which delay orders. ## 3. Jenburkt Wellness: the over-the-counter bet on direct-to-consumer **A consumer division launched in 2021 that sells natural pain-relief products online and in retail stores - a complete departure from the prescription-only model, built around a single brand, Zixa Strong, that the company is turning into a sports-and-wellness franchise.** - **Born digital, now omnichannel** - Zixa Strong was the company’s first over-the-counter product, launched on Amazon and 1mg in 2022, and has since expanded from 3 pilot cities to 10 in general trade, with a dedicated field force placing it on physical retail shelves. - **A pain-relief product with a technology story** - Zixa Strong uses an Oil-in-Water FlashMicelle Technology to deliver simultaneous hot and cold therapy, is made from plant-based ingredients without artificial preservatives or parabens, and was launched in roll-on, spray and gel formats - the first brand to offer all three in a single formulation. - **Credibility is borrowed from sport and science** - the brand is the Official Pain Relief and Recovery Partner of Mumbai City FC, carries a recommendation from the Indian Association of Physiotherapists (a community of over 12,000 physiotherapists), and has been the pain-relief partner at over 80 events including the Ladakh Marathon and the Adani Ahmedabad Marathon. - **The range is broadening fast** - what started as a rapid-pain-relief roll-on now includes an ortho pain massage oil, a headache roll-on, a muscle recovery gel, a period-cramp relief roll-on, sports recovery oil, and even energy drinks with BCAA and sugar-free variants. # Shared manufacturing and R&D backbone **A single plant and a government-recognised R&D centre in Sihor, Gujarat, supply all three engines - the company makes nothing elsewhere and tests everything itself.** - **One plant, multiple regulators** - the Sihor facility is WHO-GMP compliant and approved under Schedule-M of the Drugs and Cosmetics Act, with a workforce that is 54% women. - **R&D that chases firsts** - the in-house centre, now named the Shri Hemendra Bhuta Research Centre, has held DSIR recognition since 2010 and has produced several first-in-the-world fixed-dose combinations, including Nervijen, Nervijen-P and Metmin-A. - **Raw-material sourcing is direct but exposed** - the company buys 95% of its materials straight from manufacturers, yet like all Indian pharma firms it depends on China for roughly 70-80% of the country’s API supply, a vulnerability it flags repeatedly. - **Quality systems run deep** - a cross-functional team called QUEST has been in place since 2007, and the plant operates with a Laboratory Information Management System and a custom supply-chain tool called Q-Logie alongside its SAP S/4HANA core. # Group structure and partners **Jenburkt is a standalone, debt-free company with no subsidiaries and no foreign collaborators - it is promoter-led, listed only on the BSE, and has recently bought adjacent land to expand its sole manufacturing site.** - **No corporate layers** - the company has no holding company, subsidiary or associate, and no foreign investments or collaborators. - **Promoter-held but with public float** - after a 2023 buyback that retired 1,76,078 shares, promoter and promoter-group shareholding stood at 47.56%, with the public holding the remaining 52.44%. - **Leadership is long-tenured** - Chairman and Managing Director Ashish U. Bhuta has been with the company since 1994 and was recently re-appointed through 2031; Whole-Time Director and CFO Dilip H. Bhuta has been re-appointed through 2032. - **Land for the next chapter** - in March 2025 the company registered agreements for two adjacent plots totalling 3,160 square metres in GIDC Sihor, close to its existing plant, following a board proposal first considered in 2021 to set up a modern formulations unit.